Rituximab for remission induction in recurrent ANCA-associated glomerulonephritis postkidney transplant

Transplant International

Volumn 26, Issue 12, 2013, Pages 1225-1231

  Murakami, Christine ^a   Manoharan, Pradeep ^b   Carter Monroe, Naima ^a   Geetha, Duvuru ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Apollo Hospitals   (India)

Author keywords

ANCA vasculitis; glomerulonephritis; kidney transplantation; outcomes; recurrence; rituximab

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CHLORAMBUCIL; CREATININE; CYCLOPHOSPHAMIDE; ECULIZUMAB; GLUCOCORTICOID; HLA A24 ANTIGEN; HLA ANTIBODY; HLA DR11 ANTIGEN; HLA DR5 ANTIGEN; HLA DR52 ANTIGEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANCA ASSOCIATED GLOMERULONEPHRITIS; ARTICLE; BIOPSY; CLINICAL ARTICLE; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DIALYSIS; FEMALE; FOLLOW UP; GLOMERULONEPHRITIS; GRAFT REJECTION; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; PLASMAPHERESIS; PNEUMONIA; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; TREATMENT OUTCOME;

ANCA VASCULITIS; GLOMERULONEPHRITIS; KIDNEY TRANSPLANTATION; OUTCOMES; RECURRENCE; RITUXIMAB;

ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CYCLOPHOSPHAMIDE; FEMALE; GLOMERULONEPHRITIS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; REMISSION INDUCTION;

EID: 84888031106     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12203     Document Type: Article

References (37)

1. Flossmann O, Berden A, de Groot K, et al,. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011; 70: 488.
2. Franssen CF, Stegeman CA, Oost-Kort WW, et al,. Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glomerulonephritis. J Am Soc Nephrol 1998; 9: 1915.
3. Booth AD, Almond MK, Burns A, et al,. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003; 41: 776.
4. Hogan SL, Falk RJ, Chin H, et al,. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005; 143: 621.
5. Schnuelle P, Lorenz D, Trede M, Van Der Woude FJ,. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol 1998; 9: 2135.
6. Wolfe RA, Ashby VB, Milford EL, et al,. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725.
7. Schmitt WH, van der Woude FJ,. Organ transplantation in the vasculitides. Curr Opin Rheumatol 2003; 15: 22.
8. Fauci AS, Balow JE, Brown R, et al,. Successful renal transplantation in Wegener's granulomatosis. Am J Med 1976; 60: 437.
9. Lyons GW, Lindsay WG,. Renal transplantation in a patient with Wegener's granulomatosis. Am J Surg 1972; 124: 104.
10. Moises J, Torregrosa JV, Ybarra J, Oppenheimer F,. Renal transplantation in a C-ANCA(+) patient with Behcet disease and rapidly progressive glomerulonephritis. Clin Nephrol 2004; 61: 357.
11. Besbas N, Ozaltin F, Tinaztepe K, et al,. Successful renal transplantation in a child with ANCA-associated microscopic polyangiitis. Pediatr Nephrol 2003; 18: 696.
12. Moroni G, Torri A, Gallelli B, et al,. The long-term prognosis of renal transplant in patients with systemic vasculitis. Am J Transplant 2007; 7: 2133.
13. Marco H, Mirapeix E, Arcos E, et al,. Long-term outcome of antineutrophil cytoplasmic antibody-associated small vessel vasculitis after renal transplantation. Clin Transplant 2013; 27: 338.
14. Allen A, Pusey C, Gaskin G,. Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 1998; 9: 1258.
15. Cohen BA, Clark WF,. Pauci-immune renal vasculitis: natural history, prognostic factors, and impact of therapy. Am J Kidney Dis 2000; 36: 914.
16. Frasca GM, Neri L, Martello M, Sestigiani E, Borgnino LC, Bonomini V,. Renal transplantation in patients with microscopic polyarteritis and antimyeloperoxidase antibodies: report of three cases. Nephron 1996; 72: 82.
17. Grotz W, Wanner C, Rother E, Schollmeyer P,. Clinical course of patients with antineutrophil cytoplasm antibody positive vasculitis after kidney transplantation. Nephron 1995; 69: 234.
18. Haubitz M, Kliem V, Koch KM, et al,. Renal transplantation for patients with autoimmune diseases: single-center experience with 42 patients. Transplantation 1997; 63: 1251.
19. Kuross S, Davin T, Kjellstrand CM,. Wegener's granulomatosis with severe renal failure: clinical course and results of dialysis and transplantation. Clin Nephrol 1981; 16: 172.
20. Rostaing L, Modesto A, Oksman F, Cisterne JM, Le Mao G, Durand D,. Outcome of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis following cadaveric kidney transplantation. Am J Kidney Dis 1997; 29: 96.
21. Schmitt WH, Haubitz M, Mistry N, Brunkhorst R, Erbsloh-Moller B, Gross WL,. Renal transplantation in Wegener's granulomatosis. Lancet 1993; 342: 860.
22. Wrenger E, Pirsch JD, Cangro CB, et al,. Single-center experience with renal transplantation in patients with Wegener's granulomatosis. Transpl Int 1997; 10: 152.
23. Clarke AE, Bitton A, Eappen R, Danoff DS, Esdaile JM,. Treatment of Wegener's granulomatosis after renal transplantation: is cyclosporine the preferred treatment? Transplantation 1990; 50: 1047.
24. Hoffman GS, Kerr GS, Leavitt RY, et al,. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488.
25. Furuta S, Jayne DR,. Antineutrophil cytoplasm antibody-associated vasculitis: recent developments. Kidney Int 2013; 84: 244.
26. Stone JH, Merkel PA, Spiera R, et al,. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221.
27. Jones RB, Tervaert JW, Hauser T, et al,. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 211.
28. Geetha D, Seo P, Specks U, Fervenza FC,. Successful induction of remission with rituximab for relapse of ANCA-associated vasculitis post-kidney transplant: report of two cases. Am J Transplant 2007; 7: 2821.
29. Jennette JC,. Rapidly progressive crescentic glomerulonephritis. Kidney Int 2003; 63: 1164.
30. Stone JH, Hoffman GS, Merkel PA, et al,. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001; 44: 912.
31. Nachman PH, Segelmark M, Westman K, et al,. Recurrent ANCA-associated small vessel vasculitis after transplantation: a pooled analysis. Kidney Int 1999; 56: 1544.
32. de Groot K, Harper L, Jayne DR, et al,. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150: 670.
33. Huugen D, Tervaert JW, Heeringa P,. Antineutrophil cytoplasmic autoantibodies and pathophysiology: new insights from animal models. Curr Opin Rheumatol 2004; 16: 4.
34. Smith RM, Jones RB, Guerry MJ, et al,. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64: 3760.
35. Barnett AN, Hadjianastassiou VG, Mamode N,. Rituximab in renal transplantation. Transpl Int 2013; 26: 563.
36. Rutgers A, Kallenberg CG,. Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis. Curr Opin Rheumatol 2012; 24: 245.
37. Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suarez LF, van der Woude FJ,. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004; 65: 1440.